Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2026 09:49 ET | Source: BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder

BD² Launches Data Science Fellowship for Early Career Scientists

Washington, D.C., June 01, 2026 (GLOBE NEWSWIRE) -- Highlights: BD² plans to award eight new data science fellowships for early career investigators to advance bipolar disorder research....
June 01, 2026 07:15 ET | Source: Novartis Pharma AG

Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML

Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1 Clinically relevant 15.2%...
May 31, 2026 01:15 ET | Source: Novartis Pharma AG

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent...
May 21, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali® NATALEE oral presentation to report...
May 18, 2026 07:18 ET | Source: Research and Markets

Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading

Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Life Science Instrumentation Market by Technology, Application, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's...
May 17, 2026 15:30 ET | Source: Novartis Pharma AG

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12,...
May 06, 2026 09:19 ET | Source: Research and Markets

Opportunity Insights for the $1.1 Billion Preclinical Imaging Industry, 2026 - Bruker Corp., Cubresa, and Siemens Healthineers Lead

Dublin, May 06, 2026 (GLOBE NEWSWIRE) -- The "Preclinical Imaging Industry Analysis, Size, Share, Growth, Trends, and Forecast 2026-2033 - (by Product Type, Application, End-User, Geographic...
April 07, 2026 12:01 ET | Source: Research and Markets

Messenger RNA (mRNA) Market Projected to Reach $20.99 Billion by 2035 - Moderna, Pfizer, and Others Propel mRNA Expansion into New Therapeutic Areas

Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Messenger RNA Market - A Global and Regional Analysis: Application and Regional Analysis - Analysis and Forecast, 2025-2035" has been added to ...
February 25, 2026 07:00 ET | Source: Novartis Pharma AG

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands...
February 25, 2026 07:00 ET | Source: Novartis Pharma AG

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands...